MEGHANA TRIVEDI to Female
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Female.
Connection Strength
0.377
-
Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic. Int J Clin Pharm. 2023 Dec; 45(6):1396-1404.
Score: 0.026
-
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Pharmacoeconomics. 2023 06; 41(6):709-718.
Score: 0.026
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
Score: 0.024
-
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer. FASEB J. 2021 07; 35(7):e21719.
Score: 0.023
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
Score: 0.021
-
Patient-reported outcomes in light of supportive medications in treatment-na?ve lung cancer patients. Support Care Cancer. 2020 Apr; 28(4):1809-1816.
Score: 0.020
-
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. BMC Cancer. 2019 Mar 12; 19(1):220.
Score: 0.019
-
Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 06; 53(6):612-620.
Score: 0.019
-
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat. 2018 Jul; 170(2):279-292.
Score: 0.018
-
Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
Score: 0.018
-
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct; 153(3):591-7.
Score: 0.015
-
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
Score: 0.014
-
The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol. 2014; 131(3):133-40.
Score: 0.013
-
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
Score: 0.013
-
Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501.
Score: 0.012
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011 Oct; 20 Suppl 3:S42-9.
Score: 0.012
-
Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2011 Jun; 17(2):85-90.
Score: 0.010
-
Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500.
Score: 0.009
-
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
Score: 0.006
-
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. Breast Cancer Res Treat. 2020 Jul; 182(2):401-409.
Score: 0.005
-
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clin Cancer Res. 2020 02 01; 26(3):738-745.
Score: 0.005
-
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance. Br J Cancer. 2019 02; 120(3):331-339.
Score: 0.005
-
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients. Ann Pharmacother. 2019 05; 53(5):501-509.
Score: 0.005
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
Score: 0.005
-
Epigenetic Silencing of THY1 Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. Mol Cancer Res. 2019 02; 17(2):628-641.
Score: 0.005
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
Score: 0.004
-
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. 2016 06; 157(2):203-210.
Score: 0.004
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.004
-
The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.
Score: 0.004
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.004
-
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 2013 Dec 01; 19(23):6389-97.
Score: 0.003
-
Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71.
Score: 0.003
-
Die and let live: harnessing BikDD to combat breast cancer stem cells. Breast Cancer Res. 2012 May 23; 14(3):310.
Score: 0.003